Status:
WITHDRAWN
Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Collaborating Sponsors:
Council of Scientific and Industrial Research, India
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
25-60 years
Phase:
PHASE4
Brief Summary
The study aims to see if there is any significant difference in the cardiovascular outcomes in type 2 diabetes patients who are treated with pioglitazone or Metformin
Eligibility Criteria
Inclusion
- Newly diagnosed (less than six months since diagnosis and not controlled on dietary modifications) type 2 diabetic patients of both sexes aged 25-60 years.
- Ready to give written informed consent
Exclusion
- Presence of ketonuria
- Severe concurrent, infection or illness
- History of hypersensitivity to any study drug
- Impaired renal function
- Pulmonary insufficiency with hypoxemia
- Severe hepatic disease
- Congestive heart failure
- History of myocardial infarction or angina(stable/unstable)
- History of alcohol or drug abuse
- Pregnant or lactating women -
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00399204
Start Date
January 1 2006
End Date
December 1 2012
Last Update
March 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PGIMER
Chandigarh, India, 160012